一项评估鲍曼尼杆菌杆菌患者中磺胺乳酰胺甲酰胺的研究
一项多中心,开放标签的1B研究,用于评估住院儿科患者在住院的儿科患者中的药代动力学,安全性和耐受性
The goal of this clinical trial is to investigate the use of Sulbactam-Durlobactam (SUL-DUR) in pediatric patients and is being conducted to collect pharmacokinetic (PK) and safety data to enable the identification of appropriate pediatric dosing regimens for patients with Acinetobacter baumannii-calcoaceticus complex (ABC) infections
研究概览
地位
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习联系方式
- 姓名:ISTX Clinical Trials
- 电话号码:617-715-3600
- 邮箱:Clinicaltrials@istx.com
学习地点
-
-
California
-
Los Angeles、California、美国、90095
- 招聘中
- UCLA Medical Center
-
San Diego、California、美国、92123
- 招聘中
- Rady Children's Hospital
-
-
North Carolina
-
Greenville、North Carolina、美国、27834
- 招聘中
- ECU Brody School of Medicine
-
-
Texas
-
Galveston、Texas、美国、77555-5302
- 招聘中
- University of Texas Medical Branch at Galveston
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Patient from birth (defined as post-natal age of 7 days) to <18 years of age at the time of written informed consent (and assent, if applicable) and is hospitalized.
- Patient and/or parent(s) or legal guardian(s) have provided the written informed consent and/or assent.
- Patient has confirmed or suspected diagnosis of ABC infection and requires IV antibiotics for treatment.
- Patient has expected survival of 30 days after enrollment in the study.
- If patient is an individual of childbearing potential or reproductive potential, then the patient must remain abstinent OR must utilize one of the highly effective methods of contraception (ie, condom, combined oral contraceptive, implant, or injectable) from at least 30 days prior to screening until at least 30 days after administration of the last dose of study drug.
Exclusion Criteria:
-
Patient is a preterm infant, born at <28 weeks gestational age.
-
Patient has history of significant hypersensitivity or allergic reaction to any β-lactam, any contraindication to the excipients used in the formulation, or any contraindication to the use of β-lactam antibiotics. Note: For β-lactams, a history of a mild rash followed by uneventful re-exposure is not a contraindication to enrollment.
-
Patient is in refractory septic shock at the time of enrollment, defined as persistent hypotension despite adequate fluid resuscitation or vasopressive therapy.
-
Patient is pregnant, breastfeeding, or intends to become pregnant.
-
Patient is receiving peritoneal dialysis or cardiopulmonary bypass.
-
Patient has received blood transfusion within 24 hours of study drug administration.
-
Patient is a newborn with clinically significant anemia who, in the opinion of the investigator, will not be able to tolerate the necessary blood draws to complete the study activities.
-
Patient (or patient's mother, if the patient is being breastfed) is using or will need to use any medications known to inhibit organic anion transporter 1 (OAT1) (eg, probenecid).
-
Patient has clinically significant renal, hepatic, or hemodynamic instability.
-
For Cohorts 1 through 3 only: patient has weight outside of the 5th to 95th percentile based on age.
-
Patient has an age-appropriate estimated creatinine clearance that indicates renal impairment.
-
Patient has the following laboratory results at Screening:
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3×upper limit of normal (ULN) and,
- Total bilirubin >2×ULN for age with conjugated/direct bilirubin >20% of the total. Note: Patients with AST or ALT up to 5×ULN are eligible if these elevations are acute and are documented as being directly related to the infectious process being treated.
-
Patient has clinically significant abnormal laboratory test results not related to the underlying infection that might expose the patient to risk by participating in the trial, confound the results of the trial, or interfere with the patient's participation for the full duration of the trial.
-
Patient (or patient's mother, if the patient is being breastfed) has participated in a clinical study involving investigational medication or an investigational device within the last 30 days or 5 half-lives, whichever is longer, prior to first dose of the study drug.
-
Patient has any condition that, in the opinion of the investigator, would compromise the safety of the patient or the quality of the data.
-
Patient is unable or unwilling, in the opinion of the investigator, to comply with the protocol.
-
Patient (or patient's mother, if the patient is being breastfed) has previously received durlobactam.
-
Patient (or patient's mother, if the patient is being breastfed) has received sulbactam and/or sulbactam-containing regimens (eg, Unasyn) within 72 hours of first dose of the study drug.
-
Patient (or patient's mother, if the patient is being breastfed) has received amphotericin B within 7 days of first dose of the study drug.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Cohort 1
Pediatric patients 12 years to <18 years of age Sulbactam 25mg/kg -Durlobactam 25mg/kg, not to exceed 1g sulbactam - 1g durlobactam (Every 6 hours) |
25mg/kg SUL and 25mg/kg DUR
其他名称:
|
|
实验性的:Cohort 2
Pediatric patients 6 years to <12 years of age Sulbactam 25mg/kg -Durlobactam 25mg/kg, not to exceed 1g sulbactam - 1g durlobactam (Every 6 hours) |
25mg/kg SUL and 25mg/kg DUR
其他名称:
|
|
实验性的:Cohort 3
Pediatric patients 1 year to <6 years of age |
25mg/kg SUL and 25mg/kg DUR
其他名称:
|
|
实验性的:Cohort 4
Pediatric patients 3 months to <1 year of age |
25mg/kg SUL and 25mg/kg DUR
其他名称:
|
|
实验性的:Cohort 5 Subgroup 1
Aged 2 months to <3 months, term and preterm (gestational age >28 weeks) Term infants will receive 25mg/kg SUL and 25mg/kg DUR Preterm infants will receive 20mg/kg SUL and 20mg/kg DUR |
25mg/kg SUL and 25mg/kg DUR
其他名称:
20mg/kg SUL and 20mg/kg DUR
其他名称:
|
|
实验性的:Cohort 5 Subgroup 2
Aged birth to <2 months, term and preterm (gestational age >28 weeks and post-natal age >7 days) Term infants will receive 25mg/kg SUL and 25mg/kg DUR Preterm infants will receive 20mg/kg SUL and 20mg/kg DUR |
25mg/kg SUL and 25mg/kg DUR
其他名称:
20mg/kg SUL and 20mg/kg DUR
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
评估Sulbactam和Durlobactam的最大浓度(CMAX)的药代动力学(PK)参数
大体时间:第1天和第3天
|
第1天和第3天
|
|
评估血浆浓度时间曲线下面积的PK参数,从0到24小时(AUC 0-24)和Durlobactam
大体时间:第1天和第3天
|
第1天和第3天
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
严重 TEAE 的发生率
大体时间:28天
|
28天
|
|
|
导致研究药物停用的茶的百分比
大体时间:28天
|
28天
|
|
|
相关茶的发病率
大体时间:28天
|
28天
|
|
|
通过综合代谢面板(CMP)测量的肝功能的基线值的变化
大体时间:基线和第28天
|
基线和第28天
|
|
|
与CMP测量的肾功能的基线值的变化
大体时间:基线和第28天
|
基线和第28天
|
|
|
从血红蛋白的基线值变化
大体时间:基线和第28天
|
基线和第28天
|
|
|
从白细胞计数的基线价值变化
大体时间:基线和第28天
|
基线和第28天
|
|
|
从血小板的基线价值变化
大体时间:基线和第28天
|
基线和第28天
|
|
|
从舒张压的基线价值变化
大体时间:基线和第28天
|
基线和第28天
|
|
|
从收缩压的基线值变化
大体时间:基线和第28天
|
基线和第28天
|
|
|
从心率的基线值变化
大体时间:基线和第28天
|
基线和第28天
|
|
|
从呼吸速率的基线价值变化
大体时间:基线到第28天
|
基线到第28天
|
|
|
从温度的基线值变化
大体时间:基线和第28天
|
基线和第28天
|
|
|
Percentage of participants experiencing Treatment Emergent Adverse Events (TEAEs)
大体时间:28 days
|
Defined as any adverse event occurring after exposure to the study drug or any AE that worsens in intensity or frequency |
28 days
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- CS2514-2023-002
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 共享时间框架
Data requests may be submitted starting 6 months after primary article publication and the data will be made accessible for up to 24 months; extensions may be considered on a case-by-case basis. Access criteria: Subject to certain criteria, conditions, and exceptions and upon completion of the review
IPD 共享访问标准
Subject to certain criteria, conditions, and exceptions and upon completion of the review and approval of the Research Proposal and Statistical Analysis Plan, Qualified Researchers engaging in independent scientific research can be provided de-identified IPD following the execution of a Data Sharing Agreement
IPD 共享支持信息类型
- 研究方案
- 树液
- 国际碳纤维联合会
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.